ESC 365 - Combined sodium-glucose-transporters inhibitors (SGLT2i) and glucagon-like-peptide receptor agonist (GLP1ra) compared with SGLT2i or GLP1ra alone improves survival: a Real-World Registry

ESC Professional Premium Access

Combined sodium-glucose-transporters inhibitors (SGLT2i) and glucagon-like-peptide receptor agonist (GLP1ra) compared with SGLT2i or GLP1ra alone improves survival: a Real-World Registry

Session: Repurposing anti-diabetic pharmacotherapy: the new cure for all evils?

Topic: Antidiabetic Pharmacotherapy

Speaker: Doctor D. Garcia Vega (Santiago de Compostela, ES)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor David Garcia Vega

University Hospital of Santiago de Compostela, Santiago de Compostela (Spain)

0 follower

3 more presentations in this session

State-of-the-art lecture on repurposing of diabetic medications: the new cure for all evils?

Speaker: Associate Professor A. Navar (Dallas, US)

Impact of SGLT2 inhibitors on liver-related outcomes in patients with heart failure - a population-based study in HK

Speaker: Ms H. Yang (Hong Kong, HK)

Risk of Incident colorectal carcinoma in patients with type 2 diabetes on SGLT-2 inhibitor users: a population-based cohort study

Speaker: Doctor G. Jong (Taichung, TW)

Access the full session

Repurposing anti-diabetic pharmacotherapy: the new cure for all evils?

Speakers: Doctor D. Garcia Vega, Associate Professor A. Navar, Ms H. Yang, Doctor G. Jong

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources